Nac Ratiopharm (Acetylcysteine)

Acetylcysteine, the active ingredient in Nac Ratiopharm, is a mucolytic presented as an oral formulation for oral use. It reduces mucus viscosity and is employed in the management of chronic respiratory conditions such as chronic bronchitis, COPD and cystic fibrosis.

GNH USA supplies Nac Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and consistent product availability across multiple markets.

Acetylcysteine is used as a mucolytic agent to improve airway clearance in several chronic respiratory diseases. - Chronic bronchitis: helps thin mucus, facilitating expectoration and reducing cough frequency. - Chronic obstructive pulmonary disease (COPD): reduces sputum viscosity, aiding breathing and decreasing exacerbation severity. - Cystic fibrosis: improves mucus clearance from the lungs, supporting respiratory function and infection control.

Acetylcysteine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild stomach discomfort often reported after oral intake. - Vomiting: occasional expulsion of stomach contents. - Diarrhea: loose stools occurring within hours of dosing. - Abdominal pain: cramping or discomfort in the stomach area. - Headache: transient mild headache.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with rash, swelling, and breathing difficulty. - Bronchospasm: sudden narrowing of airways causing wheezing. - Hepatotoxicity: rare liver enzyme elevation indicating liver stress. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Hemolysis in G6PD deficiency: rapid breakdown of red blood cells.

When prescribing acetylcysteine, clinicians should consider several safety measures to minimise risk. - Assess renal function: dose may need adjustment in severe renal impairment. - Monitor for hypersensitivity: discontinue if rash, itching or swelling develop. - Caution in asthma: observe for bronchospasm after administration. - Avoid concurrent strong oxidants: may reduce antioxidant benefit. - Pregnancy and lactation: use only if potential benefit outweighs risk, after professional evaluation. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Acetylcysteine can interact with other medicines, influencing their effectiveness or safety profile.

Major Interactions (Avoid): - Nitrofurantoin: concurrent use may increase risk of hemolysis in G6PD‑deficient patients. - Activated charcoal: may bind acetylcysteine and reduce its absorption.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): acetylcysteine may enhance anticoagulant effect, requiring INR monitoring. - Chemotherapeutic agents (cisplatin): potential additive nephrotoxicity, monitor renal function. - Carbonyl‑containing drugs (e.g., carbamazepine): may alter metabolism, watch for altered plasma levels.